Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

The following table summarizes revenue by revenue source as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
Major Products/Service Lines (in thousands)	2024		2023		2024		2023
Product revenue, net(1)	$	392,756	$	314,084	$	762,069	$	606,340
License and royalty revenues	1,335		7,616		1,997		16,144
Total revenues	$	394,091	$	321,700	$	764,066	$	622,484

________________________________

(1)The Company’s product revenue includes PYLARIFY and DEFINITY among other products. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

Revenue by product category on a net basis is as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2024		2023		2024		2023
PYLARIFY	$	273,255	$	210,522	$	532,125	$	405,992
Other radiopharmaceutical oncology	—		818		384		1,535
Total radiopharmaceutical oncology	273,255		211,340		532,509		407,527
DEFINITY	78,100		70,529		154,664		139,353
TechneLite	28,186		21,594		49,900		42,580
Other precision diagnostics	5,825		5,454		11,757		11,261
Total precision diagnostics	112,111		97,577		216,321		193,194
Strategic partnerships and other revenue	8,725		12,783		15,236		21,763
Total revenues	$	394,091	$	321,700	$	764,066	$	622,484